Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Enforcement against opioid drug makers and distributors escalates

Jaclyn Jaeger | November 7, 2017

Here’s a riddle: What’s the difference between drug dealers and prescription opioid pharmaceutical manufacturers and distributors?

The answer: nothing.

At least, that’s the loud and clear message coming from the Department of Justice, which has in recent weeks warned that it has its sights squarely on several pharmaceutical manufacturers and distributors for their role in the opioid epidemic that President Trump in October declared a national public health emergency.

The Department of Justice announced one of its most significant actions to date in September, when a bipartisan coalition of 41 state attorneys general from across the country served subpoenas to, and demanded information and documents from, several major prescription opioid drug manufacturers and distributors, as part of a multistate investigation into...

Buy this article for $49, or subscribe to Compliance Week for a month at $149 and get unlimited article access for 30 days.